ArticleJCEM case reports2025
Anti-Vascular Endothelial Growth Factor Crunch Syndrome in Proliferative Diabetic Retinopathy.
Article in JCEM case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Adjuvant Anti-VEGF in Vitrectomy for Proliferative Diabetic Retinopathy: Current Evidence, Timing Considerations, and Clinical Implications.Current ophthalmology reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A 33-year-old male individual with proliferative diabetic retinopathy (PDR) received a single intravitreal injection of conbercept (Kanghong Inc., Chengdu, China) for vitreous hemorrhage in his right eye. Three days post-injection, his vision deteriorated from 20/25 to hand motion, with anti-vascular endothelial growth factor (VEGF) crunch syndrome progressing to tractional retinal detachment, threatening the macula. Urgent surgical interventions, including vitrectomy, membranectomy, pan-retinal photocoagulation, and silicone oil tamponade, were performed. However, at the 3-month follow-up, visual acuity remained limited to counting fingers. This case highlights crunch syndrome as a rare but serious complication of intravitreal anti-VEGF therapy for PDR, emphasizing the need for careful patient selection and close postoperative monitoring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.